Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Tryp Therapeutics Inc. (TRYPF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3100-0.0034 (-1.08%)
At close: 3:27PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3134
Open0.3134
BidN/A x N/A
AskN/A x N/A
Day's Range0.3000 - 0.3226
52 Week Range0.2701 - 1.0400
Volume12,915
Avg. Volume104,615
Market Cap20.559M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Tryp Therapeutics Reports Clinical Hold on Proposed Phase 2a Study in Eating Disorders

    San Diego, California--(Newsfile Corp. - October 20, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the U.S. Food and Drug Administration ("FDA") has placed a clinical hold on the Company's Phase 2a study for eating disorders that includes binge eating disorder and hypothalamic obesity. The notification from the FDA did not provide

  • CNW Group

    KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

    Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.

  • Newsfile

    Tryp Therapeutics Announces Inclusion in AdvisorShares Psychedelics ETF

    San Diego, California--(Newsfile Corp. - October 14, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today its inclusion in the AdvisorShares Psychedelics ETF (the "Fund"), currently trading under the ticker symbol "PSIL" on the NYSE Arca exchange.The Fund is actively trading and focuses on companies that devote a majority of assets to psychedelic drug develop

Advertisement
Advertisement